The real challenges in next generation sequencing for solid tumors

Y. Altschuler (Jerusalem, Israel)

Source: International Congress 2014 – Understanding the benefit of current personalised medicine platforms
Session: Understanding the benefit of current personalised medicine platforms
Session type: Symposium
Number: 2833

WebcastSlide presentationMultimedia files

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Y. Altschuler (Jerusalem, Israel). The real challenges in next generation sequencing for solid tumors. International Congress 2014 – Understanding the benefit of current personalised medicine platforms

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Very early detection of small clones harbouring EGFR mutations in NSCLC by 2nd generation sequencing
Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics
Year: 2011


Next-generation sequencing and assessment of tumour mutational burden: are these tools ready for clinical routine use?
Source: International Congress 2019 – Molecular profiling and personalised treatment concepts in advanced non-small cell lung cancer: pertinent clinical dilemmas
Year: 2019


Identification of pleural infection microbiological patterns by applying next generation sequencing and bioinformatics analysis
Source: Virtual Congress 2020 – Antibiotic therapy for pneumonia and pleural infections
Year: 2020



High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications
Source: Eur Respir J 2009; 33: 489-506
Year: 2009



The EGFR mutation detection in NSCLC by Next Generation Sequencing (NGS): cons and pros
Source: International Congress 2019 – New molecular signatures in COPD, lung cancer and a1-antitrypsin deficiency
Year: 2019

A new integrated PCR and microarray lab-on-chip for rapid MDR tuberculosis diagnosis
Source: Annual Congress 2011 - Tuberculosis: from bench to bedside
Year: 2011

Comparative analysis of lung cancer driver mutations from FFPE samples and liquid biopsies by IonTorrent next generation sequencing
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016


Microfluidics and HPLC analyses of novel lung cancer genes identified by arbitrarily primed PCR
Source: Eur Respir J 2005; 26: Suppl. 49, 456s
Year: 2005

Combined simultaneous analysis of the automated cyto-morphology and I-FISH on the same cell, as a novel method to detect a small population of lung cancer cells
Source: Eur Respir J 2006; 28: Suppl. 50, 335s
Year: 2006

Defining lineage relationships of multiple lung tumors through shared large genomic rearrangements
Source: Annual Congress 2013 –New strategies in epigenomic research to study lung diseases (DNA rearrangements, RNA, methylation, proteosome)
Year: 2013

Second primary lung cancers developed following different system tumors
Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer
Year: 2011


The challenges of coupling new diagnostics and treatment capacity at country level
Source: Annual Congress 2013 –PG7 Tuberculosis: innovations in clinical and public health management
Year: 2013



The detection of EGFR mutations in liquid biopsy by allele-specific qPCR – the comparative evaluation of two common diagnostic tests
Source: International Congress 2018 – Genetics in chronic pulmonary diseases
Year: 2018

Utilising data from single cell approaches to study existing and recently emerging lung diseases?
Source: Virtual Congress 2021 – Utilising data from single cell approaches to study existing and recently emerging lung diseases?
Year: 2021

Radiomics in lung cancer: progress and challenges
Source: Virtual Congress 2021 – Chinese programme 2021
Year: 2021


Applications of CRISPR technology to lung cancer research
Source: Eur Respir J, 59 (1) 2102610; 10.1183/13993003.02610-2021
Year: 2022



Treatment sequencing in NSCLC EGFR+ – real-world data
Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Year: 2020


Diagnostic utility of PNA-LNA PCR clamp method for detection of EGFR exon 19 deletions and exon 21 codon L858 mutations in NSCLC samples with low tumor cells content
Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease
Year: 2012